For the quarter ended March 2023, Catalent (CTLT - Free Report) reported revenue of $1.04 billion, down 18.5% over the same period last year. EPS came in at -$0.09, compared to $1.04 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $930.44 million, representing a surprise of +11.45%. The company delivered an EPS surprise of +30.77%, with the consensus EPS estimate being -$0.13.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Catalent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- United States: $685 million compared to the $687.47 million average estimate based on two analysts.
- Elimination of revenue: -$33 million versus -$34.63 million estimated by two analysts on average.
- Revenue- International Other: $79 million compared to the $76.80 million average estimate based on two analysts.
- Revenue- Europe: $306 million versus the two-analyst average estimate of $310.16 million.
- Revenue- Biologics: $475 million versus $569.64 million estimated by four analysts on average.
- Revenue- Pharma and Consumer Health: $563 million versus $524.60 million estimated by four analysts on average.
- Revenue- Pharma and Consumer Health- Manufacturing & commercial product supply: $349 million versus the two-analyst average estimate of $310.21 million.
- Revenue- Pharma and Consumer Health- Development services & clinical supply: $214 million versus $201.91 million estimated by two analysts on average.
- Revenue- Manufacturing & commercial product supply Total: $482 million versus $405.21 million estimated by two analysts on average.
- Revenue- Development services & clinical supply Total: $556 million versus $634.60 million estimated by two analysts on average.
- Revenue- Biologics- Manufacturing & commercial product supply: $133 million compared to the $95 million average estimate based on two analysts.
- Revenue- Biologics- Development services & clinical supply: $342 million compared to the $432.70 million average estimate based on two analysts.
View all Key Company Metrics for Catalent here>>>Shares of Catalent have returned +28.9% over the past month versus the Zacks S&P 500 composite's +5.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Top 5 Dividend Stocks for Your Retirement
Zacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.
Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.
See our Top 5 now – the report is FREE >>
For the quarter ended March 2023, Catalent (CTLT - Free Report) reported revenue of $1.04 billion, down 18.5% over the same period last year. EPS came in at -$0.09, compared to $1.04 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $930.44 million, representing a surprise of +11.45%. The company delivered an EPS surprise of +30.77%, with the consensus EPS estimate being -$0.13.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Catalent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- United States: $685 million compared to the $687.47 million average estimate based on two analysts.
- Elimination of revenue: -$33 million versus -$34.63 million estimated by two analysts on average.
- Revenue- International Other: $79 million compared to the $76.80 million average estimate based on two analysts.
- Revenue- Europe: $306 million versus the two-analyst average estimate of $310.16 million.
- Revenue- Biologics: $475 million versus $569.64 million estimated by four analysts on average.
- Revenue- Pharma and Consumer Health: $563 million versus $524.60 million estimated by four analysts on average.
- Revenue- Pharma and Consumer Health- Manufacturing & commercial product supply: $349 million versus the two-analyst average estimate of $310.21 million.
- Revenue- Pharma and Consumer Health- Development services & clinical supply: $214 million versus $201.91 million estimated by two analysts on average.
- Revenue- Manufacturing & commercial product supply Total: $482 million versus $405.21 million estimated by two analysts on average.
- Revenue- Development services & clinical supply Total: $556 million versus $634.60 million estimated by two analysts on average.
- Revenue- Biologics- Manufacturing & commercial product supply: $133 million compared to the $95 million average estimate based on two analysts.
- Revenue- Biologics- Development services & clinical supply: $342 million compared to the $432.70 million average estimate based on two analysts.
View all Key Company Metrics for Catalent here>>>Shares of Catalent have returned +28.9% over the past month versus the Zacks S&P 500 composite's +5.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Top 5 Dividend Stocks for Your Retirement
Zacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.
Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.
See our Top 5 now – the report is FREE >>
Get the latest research report on CTLT - FREE